PerkinElmer said it will acquire ViaCell for $300 million in a deal that would allow it to expand its genetic screening business and its product offerings in the field of neonatal and prenatal health care. The proposed acquisition of ViaCell, developer of ViaCord -- a product that offers parents a chance to preserve their infant's umbilical cord blood for future medical use -- could conclude this year and is subject to shareholder and regulatory approval.

Related Summaries